One of the many things I think is great about Twitter is the direct contact it gives me with a handful of biopharma reporters who are using it.
Carl Icahn, reputed to be a late-riser, woke up to good news and bad news today.
Shares of Teva Pharmaceutical Industries are once again trading at an historic high. But they might not be there today if it weren’t for a tragedy.
The 800-pound gorilla of one industry has beaten the 800-pound gorilla of another. Teva CEO Shlomo Yanai took on Pfizer CEO Jeff Kindler and won.
I can hear the commercial now. “Underarm protection that literally makes you feel more like a man.”
Of course, I'm off the day all heck breaks loose on the beat and stocks are making big moves all over the place.
Tomorrow is the day the agency is scheduled to announce if the first once-a-week diabetes treatment, a rejiggered version of the now twice-a-day Byetta, can come to market.
On the eve of the 10-year anniversary of the dot-com bubble bursting the stock stat mavens here at CNBC sliced and diced all sorts of data on share price performance since March 10, 2000.
It's not quite the same as waiting for new, entertaining commercials during the Super Bowl, but there was a noteworthy premiere during last night's Academy Awards.
This morning, BMO Capital Markets biotech analyst Jason Zhang downgraded shares of Amylin Pharmaceuticals to the equivalent of "Sell."